The Addition of 400 cGY Total Body Irradiation to a Regimen Incorporating Once-Daily Intravenous Busulfan, Fludarabine, and Antithymocyte Globulin Reduces Relapse Without Affecting Nonrelapse Mortality in Acute Myelogenous Leukemia

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 4, 2010, Pages 509-514

  Russell, James A ^a   Irish, William ^b   Balogh, Alexander ^a   Chaudhry, M Ahsan ^a   Savoie, Mary Lynn ^a   Turner, A Robert ^c   Larratt, Loree ^c   Storek, Jan ^a   Bahlis, Nizar J ^a   Brown, Christopher B ^a   Quinlan, Diana ^a   Geddes, Michelle ^a   Zacarias, Nancy ^a   Daly, Andrew ^a   Duggan, Peter ^a   Stewart, Douglas A ^a  

^a FOOTHILLS HOSPITAL   (Canada)

^b CTI Clinical Trial and Consulting Services   (United States)

^c CROSS CANCER INSTITUTE   (Canada)

Author keywords

acute myelogenous leukemia; relapse; Total body irradiation

Indexed keywords

BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN A; FLUDARABINE; FOLINIC ACID; GANCICLOVIR; METHOTREXATE; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIBODY; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKEMIA RELAPSE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; RADIATION DOSE; RECURRENCE RISK; RETROSPECTIVE STUDY; TREATMENT OUTCOME; WHOLE BODY RADIATION; ANALOGS AND DERIVATIVES; ANIMAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; COMBINED MODALITY THERAPY; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INJECTIONS, INTRAVENOUS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIDARABINE; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 77649335735     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.11.017     Document Type: Article

References (19)

1. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 76 (1990) 1867-1871
2. Alyea E., Neuberg D., Mauch P., et al. Effect of total body irradiation dose escalation on outcome following T cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 8 (2002) 139-144
3. Shimoni A., Hardan I., Shem-Tov N., et al. Allogeneic hematopoietic stem cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 20 (2006) 322-328
4. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104 (2004) 857-864
5. Russell J.A., Turner A.R., Larratt L., et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant 13 (2007) 299-306
6. Bredeson C.N., Zhang M.J., Agovi M.A., et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant 14 (2008) 993-1003
7. Russell J.A., Savoie M.L., Balogh A., et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 cGY total body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 13 (2007) 814-821
8. Russell J.A., Chaudhry A., Booth K., et al. Early outcomes after allogeneic stem cell transplantation for leukemia and myelodysplasia without protective isolation: a 10-year experience. Biol Blood Marrow Transplant 6 (2000) 109-114
9. Russell J.A., Woodman R.C., Poon M.C., et al. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease. Bone Marrow Transplant 14 (1994) 397-401
10. Barrett J. Graft-versus-host disease. In: Treleaven J., and Barrett J. (Eds). Bone Marrow Transplantation in Practice (1992), Churchill Livingstone, Edinburgh, UK 257
11. de Lima M., Anagnostopoulos A., Munsell M., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104 (2004) 865-872
12. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced-intensity and myeloablative conditioning regimen in HLA-identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19 (2005) 2304-2312
13. McCune J.S., Batchelder A., Deeg H.J., et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 13 (2007) 853-862
14. McDonald G.B., Slattery J.T., Bouvier M.E., et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 101 (2003) 2043-2048
15. Hassan M., Ljungman P., Ringden O., et al. The effect of busulfan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 25 (2000) 915-924
16. Andersson B.S., de Lima M., Thall P.F., et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 14 (2008) 672-684
17. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 12 (2006) 560-565
18. Russell J.A., and Kangarloo S.B. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des 14 (2008) 1936-1949
19. Eapen M., Logan B.R., Confer D.L., et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 13 (2007) 1461-1468